Published on June 21, 2016 at 9:35 AM
Biologists present brand-new findings on chronic myeloid leukemia and feasible therapeutic approaches
Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. About twenty percent of adults diagnosed along with leukemia suffer from this kind of blood cancer. The healthy protein Gab2 functions as an enhancer of cancer-causing signals and is frequently present in larger quantities in CML cells compared to in healthy and balanced cells. In two studies, Freiburg researchers have actually earned brand-new discoveries concerning the partnership between CML and Gab2 and drugs that can easily break a particular resistance to Gab2 in CML cells. The team, including Dr. Tilman Brummer, Prof. Dr. Jörn Dengjel, Dr. Konrad Aumann, and Dr. Sebastian Halbach, published its findings in the journals Leukemia and Cell Communication and Signaling. Dr. Gabriele Kröner, managing director of the José Carreras Leukemia Foundation, is delighted along with the results: “Research means improvement in the battle versus diseases. Supporting innovative research projects adore this is one of our main targets at the nonprofit José Carreras Leukemia Foundation. The 200,000 euros in funding the José Carreras Leukemia Foundation contributed to the project was therefore an excellent usage of donations.”
The healthy protein Gab2 functions adore a multi-outlet electricity strip for proteins in a chain of signals: It can easily pass on a signal it receives to several enzymes at once and can easily likewise amplify the signal. As soon as a large quantity of Gab2 is present, it frequently develops cancer-causing properties. In CML cells, Gab2 amplifies the signal of the healthy protein Bcr-Abl. This healthy protein sets off certain cells in the bone marrow and in the blood to grow uncontrollably, thus allowing the cancer to spread a lot more rapidly. An approach frequently used in treating CML is to block the Bcr-Abl activity using tyrosine kinase inhibitors (TKIs). Yet even As soon as this targeted therapy is successful, it is not feasible to kill off every one of the diseased cells – particularly the leukemia stem cells in the bone marrow. Lifelong treatment is essential to maintain the ailment under control. Several leukemias gain a resistance to the TKIs used for the therapy over time, and the patient suffers a relapse. To make matters worse, there are likewise forms of primary resistance in which the leukemia cells react insufficiently to certain TKIs from the outset. The primary and acquired resistances are a significant stumbling block in the treatment of CML that is still only poorly understood.
The Freiburg group demonstrated that the drugs sorafenib and axitinib, which are currently approved only for kidney and liver cancer, are efficient in CML model units as well. In experiments on cell cultures, the 2 of these inhibitors succeeded in breaking various forms of the TKI resistance: including forms caused by added mutations of the gene Bcr-Abl too as those caused by large quantities of the healthy protein Gab2. Hence, the 2 of the drugs could serve as substitutions for treating CML – especially in patients that have actually made a resistance to the medication they have actually been receiving so far.
In addition, the researchers offered evidence that Gab2 plays an necessary portion in the improvement and spread of CML. In a mouse model in which they simulated the improvement of CML by adding Bcr-Abl to the bone marrow, a shortage of Gab2 led to a clear weakening or even a lack of symptoms. This shows that Gab2 is essential for the improvement and spread of the disease. In the future, doctors could thus usage Gab2 as a biomarker and infer the path of the ailment by measuring Gab2 levels. In addition, Gab2 could serve as a brand-new therapeutic target in the treatment of CML.
Source:
Albert-Ludwigs-Universität Freiburg
9e33649f-500f-4481-973b-4366274a4d4b|0|.0
Posted in: Medical Science News | Medical Research News | Medical Condition News | Pharmaceutical News
